LLY
Eli Lilly and Company
LLY has the edge over OPCH overall, supported by stronger fundamentals and stronger modeled upside.
OPCH
Option Care Health, Inc.
OPCH's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
OPCH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Stable |
OPCH's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
OPCH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 16x | $31.68 | — |
| Cheap | 20x | $27.79 | -12% |
| Current | 23x | $31.68 | — |
| Fair | 26x | $36.15 | +14% |
| Expensive | 38x | $52.50 | +66% |
Historical ranges are pointers, not guarantees.
OPCH has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over OPCH on the outlook, with more favorable profitability expectations.
OPCH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for OPCH, with profitability holding steady.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over OPCH on earnings, with more consistent year-over-year improvement.
OPCH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.02 | +47% |
| Q3 2026 | $1.38 | +8.7% |
| Q2 2026 | $1.32 | +4.8% |
| Q1 2026 | $1.28 | +2.4% |
| Q4 2025 | $1.27 | +3.3% |
| Q3 2025 | $1.27 | +5.8% |
| Q2 2025 | $1.26 | +5% |
| Q1 2025 | $1.25 | -18% |
| Q4 2024 | $1.23 | -17% |
OPCH earned $1.38 per share over the past year, up 8.7% from the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over OPCH on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over OPCH on profitability, with a higher operating margin.
OPCH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.5B | +4.1% |
| Q2 2026 | $1.4B | +1.9% |
| Q1 2026 | $1.4B | +1.3% |
| Q4 2025 | $1.5B | +16% |
| Q3 2025 | $1.4B | +12% |
| Q2 2025 | $1.4B | +15% |
| Q1 2025 | $1.3B | +16% |
| Q4 2024 | $1.3B | +12% |
OPCH's revenue has grown year over year every quarter since late 2020: $1.5B last quarter, up 4.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6% | +0.1 points |
| Q2 2026 | 5.9% | +0.1 points |
| Q1 2026 | 5.4% | -0.6 points |
| Q4 2025 | 6.2% | -0.7 points |
| Q3 2025 | 5.9% | -0.8 points |
| Q2 2025 | 5.8% | -0.7 points |
| Q1 2025 | 5.9% | -0.1 points |
| Q4 2024 | 6.9% | -0.6 points |
OPCH's operating margin was 6% last quarter, about level with the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over OPCH on cash flow, with more consistent year-over-year improvement.
OPCH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $108M | -17% |
| Q2 2026 | $172.5M | +112% |
| Q1 2026 | -$21.2M | -$4.6M |
| Q4 2025 | $22.2M | -14% |
| Q3 2025 | $130.2M | -14% |
| Q2 2025 | $81.2M | -56% |
| Q1 2025 | -$16.6M | +$58M |
| Q4 2024 | $25.8M | -17% |
OPCH generated $282M in free cash flow over the past year, up 28% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
OPCH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2% | -3M shares |
| 1 year | -7.7% | -12.6M shares |
| 3 years | -17% | -30M shares |
| 5 years | -17% | -30.9M shares |
| Available history | -3.7% | -5.8M shares |
OPCH has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q4 2025 | $95.1M |
| Q3 2025 | $62.5M |
| Q4 2024 | $92.6M |
| Q3 2024 | $42M |
| Q2 2024 | $78.1M |
| Q1 2024 | $40.1M |
| Q4 2023 | $75.2M |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over OPCH on leverage, with a lower net debt burden relative to earnings.
OPCH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.1x | Moderate |
| Q2 2026 | 2.4x | Moderate |
| Q1 2026 | 2.5x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 2.1x | Moderate |
| Q2 2025 | 2.3x | Moderate |
| Q1 2025 | 2.4x | Moderate |
| Q4 2024 | 1.8x | Healthy |
OPCH's net debt is about 2.1 years of its operating earnings (EBITDA), about the same as a year ago.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
OPCH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 69.8 | Neutral |
| Stochastic | 98.1 | Overbought |
OPCH's weekly RSI is 70 (neutral) and its Stochastic is 98 (overbought).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
OPCH PE vs Healthcare Sector
| Metric | OPCH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 32 | 29 | 3 pts above |
OPCH has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
OPCH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.3 | 8.2% above |
| 20 week MA | $25.6 | 24% above |
| 50 week MA | $27.3 | 16% above |
| 100 week MA | $28.6 | 11% above |
| 200 week MA | $29.5 | 7.2% above |
OPCH has climbed back above all five of its weekly moving averages, and it's now 7.2% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over OPCH on returns for 2026, with the stronger performance.
OPCH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.8 | $15.6 | +5.1% |
| 2021 | $15.6 | $28.0 | +80% |
| 2022 | $28.0 | $30.2 | +8.1% |
| 2023 | $30.2 | $33.7 | +11% |
| 2024 | $33.7 | $22.9 | -32% |
| 2025 | $22.9 | $32.6 | +43% |
| 2026 YTD | $32.6 | $31.7 | -2.8% |
OPCH has finished higher in five of the last six years. It's down 2.8% so far in 2026.